| Literature DB >> 35233267 |
Muhammad Ayaz Mustufa1,2, Zubia Zia1, Rabia Ilyas3, Rehan Khan4, Syed Naim Ul Hasan Naqvi1, Firdous Imran Ali5.
Abstract
INTRODUCTION: population-based follow-up study has been designed to investigate the contributing factors to high exposure to Aflatoxin B1 (AFB1) and the subsequent associated risk factors among hepatitis C-infected patients at a referral centre, Karachi. Pakistan. Hepatitis C infection affects millions of individuals worldwide and confers high morbidity and mortality, especially in lower middle-income countries (LMICs) including Pakistan. A literature review of recent studies has revealed that a number of hepatocellular carcinomas (HCC) cases are markedly increased in Pakistan, where one of the potential causes of HCC is hepatitis C virus. The objectives of this study were to determine frequency of Aflatoxin B1 (AFB1) exposure and other associated characteristics among hepatitis C patients at a referral centre, Karachi, Pakistan.Entities:
Keywords: Aflatoxin B1; hepatitis C-infected patients; hepatocarcinogenic; hepatotoxic; risk factor
Mesh:
Substances:
Year: 2021 PMID: 35233267 PMCID: PMC8831216 DOI: 10.11604/pamj.2021.40.247.23396
Source DB: PubMed Journal: Pan Afr Med J
physiognomies of patients and AFB1 exposure
| Physiognomies of Subjects | N | Percentage % | Exposure to AFB1 (%) | No Exposure to AFB1 (%) |
|---|---|---|---|---|
|
| ||||
| 18-19 | 3 | 3.4 | - | 3(100) |
| 20-29 | 12 | 13.6 | 3(25) | 9(75) |
| 30-39 | 18 | 20.5 | 7(38) | 11(62) |
| 40-49 | 31 | 35.2 | 12(39) | 19(61) |
| 50-59 | 18 | 20.5 | 8(44) | 10(56) |
| > 60 | 6 | 6.8 | - | 6(100) |
|
| ||||
| Male | 36 | 40.9 | 11(31) | 25(69) |
| Female | 52 | 59.1 | 19(37) | 33(63) |
|
| ||||
| None | 48 | 54.5 | 17(35) | 31(65) |
| Can read &write | 5 | 5.7 | 1(20) | 4(80) |
| Primary | 11 | 12.5 | 4(36) | 7(64) |
| < Matric | 6 | 6.8 | 1(17) | 5(83) |
| Matric | 6 | 6.8 | 3(50) | 3(50) |
| Under graduate | 6 | 6.8 | 0 | 6(100) |
| Graduate | 5 | 5.7 | 4(80) | 1(20) |
| Post graduate | 1 | 1.1 | 0 | 1(100) |
|
| ||||
| <10000 | 42 | 47.7 | 17(40) | 25(60) |
| 11000-20000 | 22 | 25.0 | 4(18) | 18(82) |
| 21000-30000 | 15 | 17.0 | 7(47) | 8(53) |
| >30000 | 9 | 10.2 | 2(22) | 7(78) |
|
| ||||
| Kacha | 35 | 39.8 | 10(29) | 25(71) |
| Pacca | 49 | 55.7 | 18(37) | 31(63) |
| Kacha & Pacca | 4 | 4.5 | 2(50) | 2(50) |
|
| ||||
| Islam | 84 | 95.5 | 30(36) | 54(64) |
| Chrisianity | 4 | 4.5 | 0 | 4(100) |
|
| ||||
| Sindhi | 10 | 11.4 | 1(10) | 9(90) |
| Urdu | 22 | 25.0 | 10(45) | 12(55) |
| Punjabi | 16 | 18.2 | 5(31) | 11(69) |
| Saraiki | 4 | 4.5 | 3(75) | 1(25) |
| Pushto | 17 | 19.3 | 5(29) | 12(71) |
| Balochi | 8 | 9.1 | 3(38) | 5(62) |
| Hindko | 10 | 11.4 | 3(30) | 7(70) |
| Others | 1 | 1.1 | 0 | 1(100) |
clinical and biochemical presentation
| Parameters | Responders (49) | Non-Responders (39) | |||
|---|---|---|---|---|---|
| Normal | Abnormal | Normal | Abnormal | p-value | |
| Pre-Hemoglobin | 28(57%) | 21(43%) | 20 (51.3%) | 19(48.7%) | 0.58 |
| Post-Hemoglobin | 17(34.6%) | 32(65.4%) | 16(41%) | 23(59%) | 0.54 |
| Bilirubin | 00 | 49(100%) | 00 | 39(100%) | 0.91 |
| Conjugated Bilirubin | (92%) | (8%) | 30(77%) | 9(23%) | 0.05* |
| ALT | 17 (34.7%) | 32 (69.3%) | 12 (30.8%) | 27 (69.2%) | 0.69 |
| Alkaline Phosphatase | 13 (26.5%) | 36 (73.5%) | 10 (26%) | 29 (74%) | 0.93 |
| GGT | 37 (75.5%) | 12 (24.5%) | 33(84.6%) | 6(15.4%) | 0.29 |
| Albumin | 47(96%) | 2(4%) | 37(95%) | 2 (5%) | 0.82 |
| Globulin | 47(96%) | 2(4%) | 39(100%) | -- | 0.20 |
| Total Protein | 49(100%) | -- | 39(100%) | -- | 0.91 |
| Serum Creatinine | 36(73.5%) | 13(26.5%) | 24(61.5) | 15(38.5%) | 0.23 |
| Uric Acid | 33(67%) | 16(33%) | 39(100%) | -- | 0.001* |
| Pre- WBC´s | 40(81.6%) | 9(18.4%) | 29(74%) | 10(26%) | 0.41 |
| Post- WBC´s | 40(81.6%) | 9(18.4%) | 31(79.5%) | 8(20.5) | 0.80 |
| Pre- Platelets | 38(77.5%) | 11(22.5%) | 33(84.6%)) | 6(15.4%) | 0.40 |
| Post- Platelets | 36(73.4%) | 13(26.6%) | 30(77%) | 9(23%) | 0.07 |
| HBA1c | 25(51%) | 24(49%) | 13 (33.3%) | 26(66.6%) | .05* |
| Prothrombin time | 35(71.4%) | 14(28.6%) | 10(26%) | 29(74%) | .001* |
Figure 1knowledge assessment of hepatitis C patients regarding disease transmission
Figure 2life style patterns of hepatitis C patients
Figure 3historical evaluation of hepatitis C patients with information about other hepatitis C infected members in family and other risks